Dose-escalation trial of lobaplatin weekly plus concurrent radiotherapy for local-regionally advanced nasopharyngeal carcinoma
10.3760/cma.j.issn.1004-4221.2020.03.003
- VernacularTitle:局部晚期鼻咽癌洛铂单周方案同期放疗初探
- Author:
Xuezhou PANG
1
;
Dong QING
;
Bin ZHAO
;
Daiyuan MA
Author Information
1. 川北医学院附属医院肿瘤科
- Keywords:
Nasopharyngeal neoplasm/concurrent chemoradiotherapy;
Lobaplatin;
Dose-limiting toxicity;
Maximum tolerated dose
- From:
Chinese Journal of Radiation Oncology
2020;29(3):171-174
- CountryChina
- Language:Chinese
-
Abstract:
Objective To define the maximum-tolerated dose (MTD) of lobaplatin (LBP) in a weekly regimen combined with concurrent radiotherapy in the treatment of locally advanced nasopharyngeal carcinoma (NPC).Methods A total of 18 cases with stage Ⅲ/Ⅳ A NPC were enrolled.Concurrent chemoradiotherapy was given to all the patients with a dose escalation of LBP.The initial dose of LBP was 15 mg/m2 with an escalating dose of 5 mg/m2.At least 3 patients were assigned into each group.Patients were proceeded into the next dose group if no dose-limiting toxicity (DLT) occurred until the MTD was achieved.Efficacy and toxicity were evaluated regularly.Results Three patients were assigned into the 10 mg/m2,3 into the 15 mg/m2,and 6 into the 20 mg/m2 and 25 mg/m2 groups,respectively.Two patients experienced DLT in the 25 mg/m2 group.Hence,the MTD was determined as 20 mg/m2.At 3 months after corresponding treatment,the remission rate of nasopharyngeal tumors and neck-positive lymph nodes of the patients was 100％.The most common toxicity was reversible bone marrow suppression.Conclusions The MTD of weekly lobaplatin plus concurrent IMRT is 20 mg/m2 for locally advanced NPC.This regimen is reliable and safe,which is worthy of further clinical study.
